Abstract

LNP 2.0+: Gene Medicine Beyond Covid

Fred Campbell, Scientific Director, NanoVation Therapeutics UK

mRNA vaccines against SARS-Cov2 have emphatically shown lipid nanoparticles (LNPs) can deliver safe and effective gene therapies in humans, can be developed at unprecedented speed, manufactured at scale and all at reasonable cost. A genetic healthcare revolution is now upon us. How quickly these new, diverse and life changing treatments come to market, however, will require many outstanding challenges to be met (both scientifically and commercially). Here, I will briefly outline NTx’s strategic and scientific efforts to accelerate the development of new LNP-based gene medicines and democratize healthcare for all.